Replies to post #6269 on Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

I agree.

With the recent PR and the upcoming analyst upgrades, we should see 50’s soon.

At the management guidance of $1.5 EPS for 2021, Halozyme’s forward PE ratio is 28. This is cheap compared to any other company with such proven/sustainable/moated year-over-year growth guidance.

This is a hidden gem. Retail investors don’t know about it because it’s not a recent IPO/SPAC, or talked about on CNBC/youtube/Robinhood, etc. Frankly, I prefer it this way.